| Characteristic . | Value . |
|---|---|
| Female sex: n (%) | 352 (74) |
| Age: median (IQR, range) | 59 (45–70, 19–92) |
| White ethnicitya: n/N (%) | 407/420 (97) |
| IMID diagnosis: n (%) | |
| RA | 167 (35) |
| PsA | 65 (14) |
| PMR | 49 (10) |
| Vasculitis | 42 (9) |
| AS | 32 (7) |
| SLE | 32 (7) |
| SS | 13 (3) |
| SSc | 9 (2) |
| Other | 59 (12) |
| None | 9 (2) |
| Immunomodulatory therapy: n (%) | |
| Prednisolone | 116 (24) |
| MTX | 145 (30) |
| SSZ | 34 (7) |
| HCQ | 45 (9) |
| LEF | 12 (3) |
| MMF | 32 (7) |
| AZA | 16 (3) |
| CYC | 3 (1) |
| Anti-TNF | 109 (23) |
| Rituximab | 66 (14) |
| Belimumab | 3 (1) |
| Abatacept | 4 (1) |
| Tocilizumab | 14 (3) |
| Ustekinumab | 1 0 |
| Secukinumab | 11 (2) |
| Ixekizumab | 1 0 |
| Anakinra | 1 0 |
| Janus kinase inhibitor | 14 (3) |
| Number of previous SARS-CoV-2 vaccine doses: n (%) | |
| 0 | 6 (1) |
| 1 | 3 (1) |
| 2 | 18 (4) |
| 3 | 245 (51) |
| 4 | 174 (36) |
| 5 | 8 (2) |
| Not recorded | 23 (5) |
| Days from symptom onset to assessment: median (IQR, range) | 3 (2–4, 0–14)b |
| Eligible for COVID-19 treatment: n/N (%) | 248/477 (52) |
| RA | 85/167 (51) |
| PsA | 34/65 (52) |
| PMR | 16/49 (33) |
| Vasculitis | 28/42 (66) |
| AS | 21/32 (66) |
| SLE | 22/32 (69) |
| SS | 3/13 (23) |
| SSc | 7/9 (77) |
| Other | 32/59 (54) |
| COVID-19 treatment received: n (%) | |
| Nirmatrelvir/ritonavir | 80 (17) |
| Sotrovimab | 98 (21) |
| Molnupiravir | 57 (12) |
| Ineligible for antiviral treatment: n (%) | 229 (48) |
| No qualifying immunosuppressive drug | 144 (30) |
| Symptom onset/test result outside treatment window | 22 (5) |
| No qualifying diagnosis | 9 (2) |
| Outside CMDU geographic area | 8 (2)c |
| Other | 46 (10) |
| Characteristic . | Value . |
|---|---|
| Female sex: n (%) | 352 (74) |
| Age: median (IQR, range) | 59 (45–70, 19–92) |
| White ethnicitya: n/N (%) | 407/420 (97) |
| IMID diagnosis: n (%) | |
| RA | 167 (35) |
| PsA | 65 (14) |
| PMR | 49 (10) |
| Vasculitis | 42 (9) |
| AS | 32 (7) |
| SLE | 32 (7) |
| SS | 13 (3) |
| SSc | 9 (2) |
| Other | 59 (12) |
| None | 9 (2) |
| Immunomodulatory therapy: n (%) | |
| Prednisolone | 116 (24) |
| MTX | 145 (30) |
| SSZ | 34 (7) |
| HCQ | 45 (9) |
| LEF | 12 (3) |
| MMF | 32 (7) |
| AZA | 16 (3) |
| CYC | 3 (1) |
| Anti-TNF | 109 (23) |
| Rituximab | 66 (14) |
| Belimumab | 3 (1) |
| Abatacept | 4 (1) |
| Tocilizumab | 14 (3) |
| Ustekinumab | 1 0 |
| Secukinumab | 11 (2) |
| Ixekizumab | 1 0 |
| Anakinra | 1 0 |
| Janus kinase inhibitor | 14 (3) |
| Number of previous SARS-CoV-2 vaccine doses: n (%) | |
| 0 | 6 (1) |
| 1 | 3 (1) |
| 2 | 18 (4) |
| 3 | 245 (51) |
| 4 | 174 (36) |
| 5 | 8 (2) |
| Not recorded | 23 (5) |
| Days from symptom onset to assessment: median (IQR, range) | 3 (2–4, 0–14)b |
| Eligible for COVID-19 treatment: n/N (%) | 248/477 (52) |
| RA | 85/167 (51) |
| PsA | 34/65 (52) |
| PMR | 16/49 (33) |
| Vasculitis | 28/42 (66) |
| AS | 21/32 (66) |
| SLE | 22/32 (69) |
| SS | 3/13 (23) |
| SSc | 7/9 (77) |
| Other | 32/59 (54) |
| COVID-19 treatment received: n (%) | |
| Nirmatrelvir/ritonavir | 80 (17) |
| Sotrovimab | 98 (21) |
| Molnupiravir | 57 (12) |
| Ineligible for antiviral treatment: n (%) | 229 (48) |
| No qualifying immunosuppressive drug | 144 (30) |
| Symptom onset/test result outside treatment window | 22 (5) |
| No qualifying diagnosis | 9 (2) |
| Outside CMDU geographic area | 8 (2)c |
| Other | 46 (10) |
Defined according to NHS Digital ethnicity codes as ‘White – British’, ‘White – Irish’ or ‘White – any other white background’ and expressed as percentage of those patients where ethnicity was recorded.
Data available for 406 assessments.
Patients were referred for assessment/treatment by other regional CMDUs.
| Characteristic . | Value . |
|---|---|
| Female sex: n (%) | 352 (74) |
| Age: median (IQR, range) | 59 (45–70, 19–92) |
| White ethnicitya: n/N (%) | 407/420 (97) |
| IMID diagnosis: n (%) | |
| RA | 167 (35) |
| PsA | 65 (14) |
| PMR | 49 (10) |
| Vasculitis | 42 (9) |
| AS | 32 (7) |
| SLE | 32 (7) |
| SS | 13 (3) |
| SSc | 9 (2) |
| Other | 59 (12) |
| None | 9 (2) |
| Immunomodulatory therapy: n (%) | |
| Prednisolone | 116 (24) |
| MTX | 145 (30) |
| SSZ | 34 (7) |
| HCQ | 45 (9) |
| LEF | 12 (3) |
| MMF | 32 (7) |
| AZA | 16 (3) |
| CYC | 3 (1) |
| Anti-TNF | 109 (23) |
| Rituximab | 66 (14) |
| Belimumab | 3 (1) |
| Abatacept | 4 (1) |
| Tocilizumab | 14 (3) |
| Ustekinumab | 1 0 |
| Secukinumab | 11 (2) |
| Ixekizumab | 1 0 |
| Anakinra | 1 0 |
| Janus kinase inhibitor | 14 (3) |
| Number of previous SARS-CoV-2 vaccine doses: n (%) | |
| 0 | 6 (1) |
| 1 | 3 (1) |
| 2 | 18 (4) |
| 3 | 245 (51) |
| 4 | 174 (36) |
| 5 | 8 (2) |
| Not recorded | 23 (5) |
| Days from symptom onset to assessment: median (IQR, range) | 3 (2–4, 0–14)b |
| Eligible for COVID-19 treatment: n/N (%) | 248/477 (52) |
| RA | 85/167 (51) |
| PsA | 34/65 (52) |
| PMR | 16/49 (33) |
| Vasculitis | 28/42 (66) |
| AS | 21/32 (66) |
| SLE | 22/32 (69) |
| SS | 3/13 (23) |
| SSc | 7/9 (77) |
| Other | 32/59 (54) |
| COVID-19 treatment received: n (%) | |
| Nirmatrelvir/ritonavir | 80 (17) |
| Sotrovimab | 98 (21) |
| Molnupiravir | 57 (12) |
| Ineligible for antiviral treatment: n (%) | 229 (48) |
| No qualifying immunosuppressive drug | 144 (30) |
| Symptom onset/test result outside treatment window | 22 (5) |
| No qualifying diagnosis | 9 (2) |
| Outside CMDU geographic area | 8 (2)c |
| Other | 46 (10) |
| Characteristic . | Value . |
|---|---|
| Female sex: n (%) | 352 (74) |
| Age: median (IQR, range) | 59 (45–70, 19–92) |
| White ethnicitya: n/N (%) | 407/420 (97) |
| IMID diagnosis: n (%) | |
| RA | 167 (35) |
| PsA | 65 (14) |
| PMR | 49 (10) |
| Vasculitis | 42 (9) |
| AS | 32 (7) |
| SLE | 32 (7) |
| SS | 13 (3) |
| SSc | 9 (2) |
| Other | 59 (12) |
| None | 9 (2) |
| Immunomodulatory therapy: n (%) | |
| Prednisolone | 116 (24) |
| MTX | 145 (30) |
| SSZ | 34 (7) |
| HCQ | 45 (9) |
| LEF | 12 (3) |
| MMF | 32 (7) |
| AZA | 16 (3) |
| CYC | 3 (1) |
| Anti-TNF | 109 (23) |
| Rituximab | 66 (14) |
| Belimumab | 3 (1) |
| Abatacept | 4 (1) |
| Tocilizumab | 14 (3) |
| Ustekinumab | 1 0 |
| Secukinumab | 11 (2) |
| Ixekizumab | 1 0 |
| Anakinra | 1 0 |
| Janus kinase inhibitor | 14 (3) |
| Number of previous SARS-CoV-2 vaccine doses: n (%) | |
| 0 | 6 (1) |
| 1 | 3 (1) |
| 2 | 18 (4) |
| 3 | 245 (51) |
| 4 | 174 (36) |
| 5 | 8 (2) |
| Not recorded | 23 (5) |
| Days from symptom onset to assessment: median (IQR, range) | 3 (2–4, 0–14)b |
| Eligible for COVID-19 treatment: n/N (%) | 248/477 (52) |
| RA | 85/167 (51) |
| PsA | 34/65 (52) |
| PMR | 16/49 (33) |
| Vasculitis | 28/42 (66) |
| AS | 21/32 (66) |
| SLE | 22/32 (69) |
| SS | 3/13 (23) |
| SSc | 7/9 (77) |
| Other | 32/59 (54) |
| COVID-19 treatment received: n (%) | |
| Nirmatrelvir/ritonavir | 80 (17) |
| Sotrovimab | 98 (21) |
| Molnupiravir | 57 (12) |
| Ineligible for antiviral treatment: n (%) | 229 (48) |
| No qualifying immunosuppressive drug | 144 (30) |
| Symptom onset/test result outside treatment window | 22 (5) |
| No qualifying diagnosis | 9 (2) |
| Outside CMDU geographic area | 8 (2)c |
| Other | 46 (10) |
Defined according to NHS Digital ethnicity codes as ‘White – British’, ‘White – Irish’ or ‘White – any other white background’ and expressed as percentage of those patients where ethnicity was recorded.
Data available for 406 assessments.
Patients were referred for assessment/treatment by other regional CMDUs.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
